panitumumab
takeda,amgen
['triplet', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'panitumumab']
should we use folfoxiri or folfox with panitumumab in ras/brafmcrc?
not supported by triplette phase-iii orr: 73% vs 76%, primary endpoint, no difference in ets, dor, ro resection
pfs: 12.3 vs. 12.7
more toxicity
os not mature
more is not always more... 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine